In brief: C3, GTG, Avantogen, Alchemia

Clinical Cell Culture (C3, ASX:CCE) will launch CellSpray XP commercially in Europe next week at a meeting in Germany. Following the launch CellSpray XP will be available for sale in those European countries where it has regulatory approval - Austria, Denmark, Germany, Italy, The Netherlands, Switzerland and the UK.

Genetic Technologies (ASX:GTG, USA:OTC:GNTLY) has received favourable rulings in its legal action against Applera Corporation in the US. The court refused Applera's request for an early ruling concerning claims language, ruled that GTG could include infringement claims against Applera's product AmpFISTR, and also ruled that particular claim construction matters already deemed favourable to GTG would not be reopened. Another formal settlement conference between the parties is scheduled for August 16.

Avantogen (ASX:ACU), formerly Australian Cancer Technology, has been granted a European patent for protection around the company's adjuvant GPI-0100 and its use as a component in vaccines. Adjuvant GPI-0100 is a modified, semi-synthetic saponin, which Avantogen acquired from Galencia in 2004, which has been shown to stimulate both the antibody and cellular components of the immune system, the company said.

Alchemia (ASX:ACL) issued $139,772 worth of shares (234,911 shares at $0.595) to its partner American Pharmaceutical Partners (APP) in consideration for APP funding 50 per cent of the development costs of synthetic heparin, with it plans to launch on the US market in 2008. Future reimbursement from APP will be via a convertible loan.